title: Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon.
abstract: An effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-mediated immune (CMI) responses against divergent HIV-1 clades. We compared anti-HIV-1 T-cell immune responses among 363 unvaccinated adults infected with diverse HIV-1 clades. Response rates to clade B Gag and/or clade B Nef in Botswana (95%) and Cameroon (98%) were similar when compared with those in countries previously studied, including Brazil (92%), Thailand (96%), South Africa (96%), Malawi (100%), and the United States (100%). Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples.
authors.affiliation: Merck and Co., Inc., Whitehouse Station, NJ, USA. swati_gupta@merck.com
authors.forename: Swati B
authors.initials: SB
authors.lastname: Gupta
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Mast
authors.forename: Nathan D
authors.initials: ND
authors.lastname: Wolfe
authors.forename: Vlad
authors.initials: V
authors.lastname: Novitsky
authors.forename: Sheri A
authors.initials: SA
authors.lastname: Dubey
authors.forename: Esper G
authors.initials: EG
authors.lastname: Kallas
authors.forename: Mauro
authors.initials: M
authors.lastname: Schechter
authors.forename: Bernard
authors.initials: B
authors.lastname: Mbewe
authors.forename: Eftyhia
authors.initials: E
authors.lastname: Vardas
authors.forename: Punee
authors.initials: P
authors.lastname: Pitisuttithum
authors.forename: Donald
authors.initials: D
authors.lastname: Burke
authors.forename: Dan
authors.initials: D
authors.lastname: Freed
authors.forename: Robin
authors.initials: R
authors.lastname: Mogg
authors.forename: Paul M
authors.initials: PM
authors.lastname: Coplan
authors.forename: Jon H
authors.initials: JH
authors.lastname: Condra
authors.forename: Romnie S
authors.initials: RS
authors.lastname: Long
authors.forename: Kiersten
authors.initials: K
authors.lastname: Anderson
authors.forename: Danilo R
authors.initials: DR
authors.lastname: Casimiro
authors.forename: John W
authors.initials: JW
authors.lastname: Shiver
authors.forename: Walter L
authors.initials: WL
authors.lastname: Straus
mesh_terms: D000293:Adolescent; D000328:Adult; D001902:Botswana; D002163:Cameroon; D002478:Cells, Cultured; D005260:Female; D015683:Gene Products, gag / Q000276:immunology; D015693:Gene Products, nef / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D037182:T-Cell Antigen Receptor Specificity; D013601:T-Lymphocytes / Q000276:immunology*; D054311:nef Gene Products, Human Immunodeficiency Virus
chemical_list: D015683:Gene Products, gag; D015693:Gene Products, nef; D015488:HIV Antigens; D054311:nef Gene Products, Human Immunodeficiency Virus; D007371:Interferon-gamma